What's new

Human medicines European public assessment report (EPAR): Hympavzi, marstacimab, Date of authorisation: 18/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Hympavzi, marstacimab, Date of authorisation: 18/11/2024, Revision: 1, Status: Authorised

Apr 28, 2025 - 16:38
 0
Human medicines European public assessment report (EPAR): Hympavzi, marstacimab, Date of authorisation: 18/11/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Hympavzi, marstacimab, Date of authorisation: 18/11/2024, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Insulet taps former J&J medtech head Ashley McEvoy to be CEO

Next Article

GE’s ascent vindicates Immelt, if only by accident

Related Posts

Summary of opinion: Vyvgart, 25/04/2025 Positive

Summary of opinion: Vyvgart, 25/04/2025 Positive

Apr 25, 2025  0

Human medicines European public assessment report (EPAR): LysaKare, arginine,lysine, Date of authorisation: 25/07/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 28, 2025  0

Business process description for orphan status management

Apr 22, 2025  0